Seeking Alpha·2d ago
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2026 Earnings Call TranscriptArcturus Therapeutics Holdings Inc. (ARCT) Q3 2026 Earnings Call Transcript
Arcturus Therapeutics' financial profile is defined by a high-intensity R&D burn rate consuming a finite cash reserve, with revenue exhibiting extreme lumpiness and lacking visibility.
Price trend, volume and key moving averages
Trailing total returns as of 11/8/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | -$0.26+62.1% vs -$0.69 | $18M+128.8% vs $8M |
Q3 2026 Aug 6, 2026 | -$0.84+15.7% vs -$1.00 | $3M-4.8% vs $3M |
Q2 2026 May 7, 2026 | -$0.95+7.4% vs -$1.03 | $2M-67.3% vs $6M |
Q2 2026 Mar 3, 2026 | -$1.03-12.0% vs -$0.92 | $7M-54.7% vs $16M |
Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2026 Earnings Call Transcript
Arcturus Therapeutics NASDAQ: ARCT expects to complete enrollment in a mid-stage cystic fibrosis study by the end of 2026 and begin dosing a next-generation treatment for a rare liver disorder in the first quarter of 2027, executives said on the company's third-quarter earnings call.
Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.6. This compares to a loss of $0.49 per share a year ago.
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #65Roses--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory therapeutics, today announced its financial results for the quarter ended September 30, 2026, and provided corporate updates. “The third quarter marked a pivotal step forward for our liver therapeutics franchise, with encouraging ARCT-810 Phase 2 results and the introduction of LUNAR 2.0™, our next-genera.
Benchmark ARCT against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Arcturus Therapeutics Holdings Inc. (ARCT)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $10.35 | $294.18M | -3.77 | -51.43% | -312.88% | -41.86% | — | |
| $254.19 | $100.86B | -39.19 | -39.23% | -110.46% | -37.62% | — | |
| $87.51 | $21.98B | -13.43 | 0.2% | -61.28% | -8.06% | — | |
| $11.35 | $1.27B | -3.73 | 16.92% | -805.75% | -64.73% | — | |
| $50.07 | $4.83B | -10.62 | -89.97% | -1812.07% | -25.59% | — | |
| $26.41 | $2.72B | -25.82 | 120.01% | -73.04% | -9.69% | — |
Arcturus Therapeutics Holdings Inc. (ARCT) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Arcturus Therapeutics Holdings Inc. (ARCT) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 6, 2026·SEC
Jul 2, 2026·SEC
Jun 5, 2026·SEC
Get notified when ARCT posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Arcturus Therapeutics Holdings Inc. (ARCT) stock FAQ — growth, dividends, profitability & financials explained
Arcturus Therapeutics Holdings Inc. (ARCT) reported $24.9M in revenue over the trailing twelve months. Revenue was $67.2M in fiscal year 2025.
Arcturus Therapeutics Holdings Inc. (ARCT) revenue fell by 72.9% over the trailing twelve months, compared with the twelve months before.
No. Arcturus Therapeutics Holdings Inc. (ARCT) reported a net loss of $78.1M over the trailing twelve months.
Arcturus Therapeutics Holdings Inc. (ARCT) had a return on equity (ROE) of -41.9% over the trailing twelve months. A negative ROE means the company lost money over the period.
Arcturus Therapeutics Holdings Inc. (ARCT) had negative free cash flow of $62.6M over the trailing twelve months.
